Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

GLAND is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 24.567165
debtToEquity 3.161000
earningsGrowth 0.278000
revenueGrowth 0.225000
grossMargins 0.588630
operatingMargins 0.193020
trailingEps 51.470000
forwardEps 71.721750

GLAND's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
Positive earnings and revenue growth for GLAND point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
Gland Pharma Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Gland Pharma Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for GLAND
Price projections for GLAND

GLAND's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect GLAND to continue delivering solid performance in the future.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


5 Gland Pharma Limited transactions were recorded, when the market price was 1913.4599853515624.The period under consideration saw no sell transactions.More recent purchases than sales at current price levels for GLAND could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


A recent buy bias from analysts toward Gland Pharma Limited may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that Gland Pharma Limited might be an appealing option for those looking to grow their wealth through stock market investments.